Prelude Therapeutics (PRLD) Revenue (2024 - 2026)

Prelude Therapeutics (PRLD) posted Revenue of $4.6 million for Q1 2026, down 18.79% sequentially from $5.6 million in Q4 2025.

Prelude Therapeutics (PRLD) Revenue (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported Revenue for 3 years, with the latest figure at $4.6 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (changed N/A YoY) and the FY2025 annual result came in at $12.1 million, up 73.43% from the prior year.
Revenue eased to $4.6 million in Q1 2026 per PRLD's latest filing, from $5.6 million in the prior quarter.
Over five years, Revenue peaked at $6.5 million in Q3 2025 and troughed at $3.0 million in Q3 2024.
A 3-year average of $4.7 million and a median of $4.6 million in 2026 frame the typical range for Revenue.
The widest YoY moves for Revenue: up 116.67% in 2025, down 41.0% in 2025.
Over 3 years, Revenue stood at $4.0 million in 2024, then jumped by 41.0% to $5.6 million in 2025, then declined by 18.79% to $4.6 million in 2026.
According to Business Quant data, Revenue over the past three periods registered $4.6 million, $5.6 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	5.70 Mn

Download Data